$0,98
▲ +$0,06
(+6,41%)
Vol. 132K
4
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$6.6M
ROE
-216,0%
Margine
-47,3%
D/E
899,15
Beta
0,53
52W
$1–$2
Consenso Wall Street
8 analisti · Apr 20262
Acquisto forte
5
Compra
1
Mantieni
0
Vendi
0
Vendita forte
87,5%
Rating Compra
Grafico dei Prezzi
Titoli simili
LPCN
Lipocine Inc
$44.6M
HIND
Vyome Holdings Inc
$19.4M
CURX
Curanex Pharmaceuticals Inc
$9.4M
TRAW
Traws Pharma Inc
$9.0M
JUNS
Jupiter Neurosciences Inc
$35.1M
CVKD
Cadrenal Therapeutics Inc
$15.9M
CALC
CalciMedica Inc
$95.0M
RVPH
Reviva Pharmaceuticals Holdings Inc
$32.1M
HOTH
Hoth Therapeutics Inc
$15.4M
SNES
Senestech Inc
$11.1M
Utili
Tasso di battuta: 20,0%
Prossimo report
Mag 13, 2026
Stima EPS: $-0,12
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,12 | — | — |
| Dic 2025 | $0,20 | $0,48 | +$0,28 |
| Set 2025 | $-0,59 | $-0,62 | $-0,03 |
| Giu 2025 | $-0,43 | $-0,57 | $-0,14 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Ricavi | $9.0M | $12.6M | $8.6M | $9.0M | $7.0M |
| Utile netto | -$5.7M | -$1.4M | -$4.2M | -$5.3M | -$6.6M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -216.0% | -216.0% | -216.0% | -216.0% | -216.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -59.0% | -30.3% | -42.3% | -42.3% | -42.3% | -47.3% |
| Gross Margin | 70.7% | 53.3% | 59.0% | 59.0% | 59.0% | 64.4% |
| D/E Ratio | — | 899.15 | 899.15 | 899.15 | 899.15 | 899.15 |
| Current Ratio | 0.96 | 1.40 | 0.96 | 0.96 | 0.96 | 1.15 |
Rapporti chiave
ROA (TTM)
-94,7%
P/S (TTM)
0,18
P/B
1,9
EPS (TTM)
$-1,84
CF/Share
$-19,36
Crescita ricavi 3A
+15,7%
52W High
$1,87
52W Low
$0,54
$0,54
Intervallo 52 settimane
$1,87
Salute finanziaria
Flusso di cassa libero
-$3.8M
Debito netto
$1.5M
Liquidità
$3.4M
Debito totale
$4.9M
Aggiornato al Set 30, 2025
Як BFRI виглядає на тлі конкурентів у Pharmaceuticals?
Група порівняння: Micro-cap Pharmaceuticals (All) · 171 компаній
Оцінка BFRI vs аналоги Pharmaceuticals
P/E
—
▼
0%
sotto
peer
(22,4)
vs Peer
vs Settore
Sottovalutato
P/S
0,2
▼
96%
sotto
peer
(5,0)
vs Peer
vs Settore
Sottovalutato
P/B
1,9
▼
10%
sotto
peer
(2,1)
vs Peer
vs Settore
Valore equo
Дивідендна дохідність
—
▼
0%
sotto
peer
(2,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість BFRI vs аналоги Pharmaceuticals
ROE
-216,0%
▼
298%
sotto
peer
(-54,3%)
vs Peer
vs Settore
Debole
Net margin
-47,3%
▲
0%
sopra
peer
(-47,4%)
vs Peer
vs Settore
Debole
Валова маржа
64,4%
▼
6%
sotto
peer
(68,3%)
vs Peer
vs Settore
Debole
ROA
-94,7%
▼
153%
sotto
peer
(-37,4%)
vs Peer
vs Settore
Debole
Фінансове здоровʼя BFRI vs аналоги Pharmaceuticals
D/E ratio
899,2
▲
58286%
sopra
peer
(1,5)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
1,2
▼
66%
sotto
peer
(3,4)
vs Peer
vs Settore
Liquidità bassa
Beta
0,5
▼
43%
sotto
peer
(0,9)
vs Peer
vs Settore
Più volatile
Радар фундаменталів BFRI
BFRI
Mediana peer
Industria
BFRI прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
BFRI vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
LUEBBERT HERMANN
Chief Executive Officer · Mar 05
137500 shs
LEFFLER EUGENE FREDERICK
Chief Financial Officer · Mar 05
87500 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 19,47%Rosalind Advisors, Inc.
9,79%
$934K
AIGH Capital Management LLC
7,86%
$750K
Vanguard Group Inc
0,98%
$93K
Geode Capital Management, L…
0,56%
$54K
Jane Street Group, LLC
0,28%
$27K
Aggiornato al Dic 31, 2025
Ultime notizie
Nessuna notizia correlata ancora